Oxford Biomedica
Pioneering gene and cell therapy with innovative viral vector solutions for pharmaceutical and biotech companies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £16.9m | Post IPO Equity | |
| Total Funding | 000k | ||
| GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 63 % | (2 %) | (36 %) | 44 % | 26 % | 30 % | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 23 % | (17 %) | (55 %) | (11 %) | 6 % | 16 % | 21 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 13 % | (28 %) | (176 %) | (34 %) | (15 %) | 2 % | 7 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 28 % | 44 % | 66 % | 4 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Oxford Biomedica is a leading player in the gene and cell therapy sector, specializing in the development and manufacturing of viral vectors. The company collaborates with top pharmaceutical and biotechnology firms to advance cell and gene therapy as a standard clinical treatment. Operating primarily in the healthcare and biotechnology markets, Oxford Biomedica leverages its proprietary LentiVector platform to deliver both ex vivo and in vivo treatments, impacting thousands of patients. The business model revolves around partnerships, research and development, and manufacturing services, generating revenue through long-term collaborations and licensing agreements. The company serves a diverse client base, including large pharmaceutical companies and innovative biotech startups, providing them with the expertise and infrastructure needed to bring advanced therapies to market.
Keywords: gene therapy, cell therapy, viral vectors, LentiVector platform, biotechnology, pharmaceutical partnerships, ex vivo treatments, in vivo treatments, healthcare innovation, manufacturing services.
Tech stack
Investments by Oxford Biomedica
Edit